# US 2022/0090070 A1 · Methods and compositions for altering function and structure of chromatin loops and/or domains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0090070 A1
- Document ID: US20220090070A1
- Status: Published application
- Kind: A1
- Application number: 17/398,951
- Filed: 2021-08-10
- Published: 2022-03-24
- Earliest claimed: 2015-08-18
- Assignees: The Broad Institute, Inc.; Baylor College of Medicine
- Applicants: The Broad Institute, Inc.; Baylor College of Medicine
- Inventors: Erez Lieberman Aiden; Eric S. Lander; Suhas Rao; Su-Chen Huang; Adrian L. Sanborn; Neva C. Durand; Miriam Huntley; Andrew Jewett
- Web page: https://patentgrep.com/patent/US20220090070A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C07K 14/47: from mammals
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Chromatin 3D structure modulating agents in the context of the present invention are intended to interfere or manipulate the function of loop anchor motifs, such as CTCF motifs. In certain example embodiments, the present invention may block formation of an loop anchor or chromatin domain or induce formation of a loop anchor or chromatin domain at a targeted genomic location. For instance, a loop anchor motif can be altered, such as by mutating (including inverting) a binding motif so as to remove such a motif, or by adding new binding motifs in new locations within a loop domain, so as to reduce the size of an existing loop, so as to modify the size of an existing loop, or combinations thereof. Alternatively, the chromatin 3D structure modulating agent may bind a target region and mask a loop anchor motif, thereby preventing a loop anchor or chromatin domain from forming. The chromatin 3D structure modulating agent may bind a target region and cause a loop anchor of chromatin domain to form.

## Claims

### Claim 1

A method to modify one or more existing chromatin loops and contact domains in a target region of chromatin DNA inside the nucleus of a cell,
wherein the target region of chromatin DNA is being extruded by each of the two subunit of a CCCTC-binding factor (CTCF) and/or cohesin-comprising extrusion complex in opposite direction with respect to the genome and wherein the target region of chromatin DNA comprises a forward and reverse CTCF or cohesin binding motif in convergent orientation on opposite strands of the extruded chromatin DNA,
said method comprising targeting one or more sequence-specific DNA targeting agents to a CTCF or cohesin binding motif or within 150,000 base pairs of a CTCF or cohesin binding motif in said target region in the nucleus of the cell, wherein the sequence-specific DNA targeting agents bind to a target site in the target region, to thereby prevent the extrusion of at least one chromatin strand through the extrusion complex.

### Claim 2 (depends on 1)

The method of claim 1, wherein said targeting comprises removal of one or more existing chromatin loops or contact domains, or the modification of one or more existing loops or contact domains.

### Claim 3 (depends on 1)

The method of claim 1, wherein the one or more sequence-specific DNA targeting agents are targeted to a location between the forward and reverse CTCF or cohesin binding motifs at an existing loop or contact domain boundary.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein said targeting being in a location within 1000 base pairs following an existing forward CTCF or cohesin binding motif.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein said one or more sequence-specific DNA targeting agents is selected from the group consisting of a catalytically inactive CRISPR/Cas system, a Cas protein, a zinc finger protein (ZFP), a zinc finger nuclease (ZFN), a transcription activator-like effector (TALE), a transcription activator-like effector nuclease (TALEN), and a meganuclease.

### Claim 13 (depends on 1)

The method of claim 1, wherein the CTCF or cohesin binding motif is the CTCF motif; and/or
wherein the extrusion complex comprises one or more members selected from the group consisting of CTCF, SA1/2, Smc3, Smc1, cohesin and Rad21.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method according to claim 1, wherein said method further comprises the step of performing in situ Hi-C on said cell prior to or following said targeting, optionally combined with HYbrid Capture on the, thereby generating an in situ Hi-C library,
wherein in situ Hi-C comprises performing Hi-C in intact nuclei, and
wherein said in situ Hi-C method identifies target chromatin loop modification sites or monitors the result of chromatin loop or contact domain modification in the target region.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein said target region comprises genes the expression of which is to be modified, preferably wherein said proximity to the target region is less than 1000 base pairs.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein targeting the one or more sequence-specific DNA targeting agents to the nucleus of a cell comprises:
delivering one or more vectors encoding the one or more sequence-specific DNA targeting agents; or
delivering a cell-permeable reagent comprising the one or more sequence-specific DNA targeting agents, preferably a pyrrole-imidazole polyamide.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the one or more sequence-specific DNA targeting agents bind to one or more existing CTCF or cohesin binding motifs.

### Claim 23 (depends on 1)

The method of claim 1, wherein the one or more sequence-specific DNA targeting agents comprise a DNA methyltransferase domain that methylates one or more existing CTCF or cohesin binding motifs in said target region.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50 (depends on 20)

The method of claim 20, wherein the one or more vectors are delivered in vivo.

### Claim 51 (depends on 20)

The method of claim 20, wherein the one or more sequence-specific DNA targeting agents are under the inducible control of a vector promoter, preferably, wherein the vector promoter is a tissue-specific promoter or a ubiquitous expression promoter.

### Claim 52

(canceled)

### Claim 53 (depends on 20)

The method of claim 20, wherein the vector is a viral vector, preferably, wherein the viral vector is selected from the group consisting of lentiviral, adenoviral, adeno-associated viral, and herpes simplex virus vectors.

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56 (depends on 1)

The method of claim 1, wherein the target region is associated with a disease, preferably,
wherein the disease is associated with aberrant chromatin folding; or
wherein the disease is cancer, a genetic disease, or infectious disease, more preferably,
wherein the target region comprises an oncogene or tumor suppressor gene, more preferably, wherein a target region associated with aberrant expression of an oncogene is targeted, whereby expression of the oncogene is repressed; or wherein a target region associated with aberrant expression of a tumor suppressor is targeted, whereby expression of the tumor suppressor is activated; or
wherein the genetic disease selected from the disorders identified in Tables A B or C, preferably, wherein the genetic disease is a disorder associated with genomic imprinting, more preferably, wherein an imprinted gene is unsilenced or wherein a gene is silenced by establishing imprinting.

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66 (depends on 1)

The method of claim 1, wherein the target region comprises a virus integration site of an infectious virus, preferably wherein the virus is a retrovirus, an adenovirus, an adeno-associated virus (AAV), a lentivirus or a herpesvirus.

### Claim 67 (depends on 1)

The method of claim 1, wherein the target region is associated with improved yields, disease resistance, drought resistance or salt tolerance in plant or animals.

### Claim 68 (depends on 1)

The method of claim 1, wherein the cells or population of cells are part of a mammal; or wherein the cells or population of cells are part of a plant.

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72

(canceled)

### Claim 73

(canceled)

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76

(canceled)

### Claim 77 (depends on 18)

The method of claim 18, further comprising detecting changes in gene expression and/or changes in cell phenotype after said targeting.

### Claim 78

(canceled)

### Claim 79

(canceled)

### Claim 80

(canceled)

### Claim 81

(canceled)

### Claim 82

(canceled)

### Claim 83

(canceled)

### Claim 84

(canceled)
